Adam J. Gadzinski, MD, MS, on the Limitations of a Study Assessing the Impact of Telemedicine on Patient-Reported Outcomes

Video

Study results revealed the impact of a rurally focused telemedicine program on patient outcomes.

Study results presented at the Society of Urologic Oncology 21st Annual Meeting determined the impact of a rurally focused telemedicine program on patient outcomes in the urologic oncology outpatient clinic at the University of Washington Medical Center (UWMC).

Through their research, the investigators determined that telemedicine provides a medium for cancer care delivery that eliminates the significant travel burden associated with in-person clinic appointments.

In an interview with CancerNetwork®, Adam J. Gadzinski, MD, MS, urologic oncology fellow and acting instructor of Urologic Oncology at the Urology Clinic at UWMC, explained the limitations of the study.

Transcription:

One of the limitations is that the survey was completed by roughly 42% of patients who were eligible for the survey. [Therefore], one limitation is [that] we don’t know what those other 58% of people thought; maybe they were the ones that hated telemedicine.

One of the other potential limitations is that we did not send the survey to patients who had what we called a “failed telemedicine visit”, or patients who were scheduled for telemedicine and then it didn't work and we had to call them on the phone. When we designed the study, we did not plan to include that group. We have kept track of who those patients were, but they did not systematically receive surveys. That’s another limitation and we don't know what the “failed telemedicine” patient-reported outcomes would be. I suspect they’d be a little less enthused about their visit.

We are planning to compare the patient characteristics of those who had a failed telemedicine visit versus a successful one. We haven’t done that yet, but that’s [on] one of our many to-do lists for the subsequent studies.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Related Content